Geistlich Pharma AG
Clinical Trials
37
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (25 trials with phase data)• Click on a phase to view related trials
Chondro-Gide® Bilayer Collagen Membrane in Knee Cartilage Defect Repair
- Conditions
- Cartilage Defects
- First Posted Date
- 2023-03-27
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Geistlich Pharma AG
- Target Recruit Count
- 140
- Registration Number
- NCT05785949
- Locations
- 🇨🇳
The Second Hospital of Jilin University, Changchun, China
🇨🇳The First Affiliated Hospital of Jinan University, Guangzhou, China
🇨🇳The Third Affiliated Hospital of Southern Medical University, Guangzhou, China
AMIC vs. MFx in the Ankle
- Conditions
- MicrofractureOsteochondral Lesion of TalusChondral Defect
- First Posted Date
- 2023-02-23
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Geistlich Pharma AG
- Registration Number
- NCT05741983
- Locations
- 🇬🇧
Freeman Hospital, Newcastle upon Tyne, United Kingdom
Evaluation of Geistlich Fibro-Gide® in Comparison to CTG for the Treatment Around Implants
- Conditions
- Soft Tissue Defect
- First Posted Date
- 2021-01-11
- Last Posted Date
- 2021-12-15
- Lead Sponsor
- Geistlich Pharma AG
- Target Recruit Count
- 60
- Registration Number
- NCT04703738
- Locations
- 🇺🇸
Regenerative Solutions, Fullerton, California, United States
🇺🇸McClain Schallhorn Periodonitcs, Aurora, Colorado, United States
🇺🇸Perio Health Professionals, Houston, Texas, United States
Clinical Study of Chondro-Gide® for Large Chondral Lesions in the Knee
- Conditions
- Cartilage InjuryCartilage DiseaseKnee InjuriesKnee Discomfort
- First Posted Date
- 2020-09-03
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Geistlich Pharma AG
- Target Recruit Count
- 234
- Registration Number
- NCT04537013
- Locations
- 🇺🇸
The MORE Foundation, Phoenix, Arizona, United States
🇺🇸Orthopaedic Foundation, Stamford, Connecticut, United States
🇺🇸Emory Sports Medicine Complex, Johns Creek, Georgia, United States
Evaluation of Geistlich Fibro-Gide® + CAF in Comparison to CTG + CAF for the Treatment of Recession Defects at 6 Months
- Conditions
- Gingival Recession
- First Posted Date
- 2020-02-07
- Last Posted Date
- 2021-08-10
- Lead Sponsor
- Geistlich Pharma AG
- Target Recruit Count
- 30
- Registration Number
- NCT04260152
- Locations
- 🇺🇸
Seven Lakes Periodontitis, Fenton, Michigan, United States
🇺🇸Perio Health Professionals, Houston, Texas, United States
🇺🇸Oral Health Specialists, Tacoma, Washington, United States
- Prev
- 1
- 2
- 3
- Next